臺灣博碩士論文加值系統

目錄
摘要 i
ABSTRACT iii
目錄 iv
圖目錄 vi
附錄目錄 ix
緒論 - 1 -
癌症 (Cancer) - 2 -
多重抗藥性 (Multidrug resistance) - 3 -
ATP-binding cassette (ABC) transporter - 4 -
ABCB1 (P-glycoprotein; MDR1) - 5 -
ABCG2 ( ABCP; BCRP; MXR ) - 6 -
WDR5-0103 - 7 -
Lazertinib (YH25448,GNS-1480) - 8 -
研究動機 - 10 -
材料與方法 - 12 -
實驗藥物與細胞培養材料 - 12 -
細胞培養(Cell culture) - 12 -
細胞存活率分析 (MTT Assay) - 15 -
細胞存活率分析 (CCK-8) - 16 -
Flow cytometry - 17 -
西方墨點法 (Western blot) - 18 -
細胞凋亡測定 (Apoptosis assay) - 20 -
量化和統計分析 - 22 -
Results - 23 -
WDR5-0103和lazertinib對細胞毒性的測試 - 23 -
WDR5-0103和lazertinib回復過度表現ABCB1的藥物敏感度能力 - 23 -
WDR5-0103和lazertinib回復過度表現ABCG2的藥物敏感度能力 - 24 -
WDR5-0103和lazertinib誘導細胞凋亡 - 25 -
WDR5-0103和lazertinib不影響ABC transporters蛋白量 - 27 -
WDR5-0103和lazertinib在ABC transporters的功能性測試 - 28 -
Discussion and Conclusion - 30 -
參考資料 - 37 -
圖表 - 43 -
附錄 - 91 -

圖目錄
Figure 1. WDR5-0103對各細胞系的毒性測試 - 43 -
Figure 2. WDR5-0103恢復過度表現ABCB1的細胞對ABCB1受質藥物paclitaxel的敏感性 - 45 -
Figure 3. WDR5-0103恢復過度表現ABCB1的細胞對ABCB1受質藥物colchicine的敏感性 - 47 -
Figure 4. WDR5-0103恢復過度表現ABCB1的細胞對ABCB1受質藥物vincristine的敏感性 - 49 -
Figure 5. WDR5-0103恢復過度表現ABCG2的細胞對ABCG2受質藥物mitoxantrone的敏感性 - 51 -
Figure 6. WDR5-0103恢復過度表現ABCG2的細胞對ABCG2受質藥物topotecan的敏感性 - 53 -
Figure 7. WDR5-0103恢復過度表現ABCG2的細胞對ABCG2受質藥物SN-38的敏感性 - 55 -
Figure 8. WDR5-0103使KB-V1細胞株對colchicine所誘導之細胞凋亡及S1-MI-80細胞株對topotecan所誘導之細胞凋亡重新感到敏感 - 58 -
Figure 9. WDR5-0103對KB-3-1和KB-V1蛋白質ABCB1表現量之影響 - 59 -
Figure 10. WDR5-0103對OVCAR-8和NCI-ADR-RES蛋白質ABCB1表現量之影響 - 60 -
Figure 11. . WDR5-0103對H460和H460- MX20蛋白質ABCG2表現量之影響 - 61 -
Figure 12. WDR5-0103對S1和S1-MI-80蛋白質ABCG2表現量之影響 - 62 -
Figure 13. WDR5-0103對ABCB1功能性之影響 - 64 -
Figure 14. WDR5-0103對ABCG2功能性之影響 - 66 -
Figure 15. Lazertinib對各細胞系的毒性測試 - 67 -
Figure 16. Lazertinib恢復過度表現ABCB1的細胞對ABCB1受質藥物paclitaxel的敏感性 - 69 -
Figure 17. Lazertinib恢復過度表現ABCB1的細胞對ABCB1受質藥物colchicine的敏感性 - 71 -
Figure 18. Lazertinib恢復過度表現ABCB1的細胞對ABCB1受質藥物vincristine的敏感性 - 73 -
Figure 19. Lazertinib恢復過度表現ABCG2的細胞對ABCG2受質藥物mitoxantrone的敏感性 - 75 -
Figure 20. Lazertinib恢復過度表現ABCG2的細胞對ABCG2受質藥物topotecan的敏感性 - 77 -
Figure 21. Lazertinib恢復過度表現ABCG2的細胞對ABCG2受質藥物SN-38的敏感性 - 79 -
Figure 22. Lazertinib使KB-V1細胞株對colchicine所誘導之細胞凋亡及S1-MI-80細胞株對topotecan所誘導之細胞凋亡重新感到敏感 - 82 -
Figure 23. Lazertinib對KB-3-1和KB-V1蛋白質ABCB1表現量之影響 - 83 -
Figure 24. Lazertinib對OVCAR-8和NCI-ADR-RES蛋白質ABCB1表現量之影響 - 84 -
Figure 25. Lazertinib對H40和H460-MX20蛋白質ABCG2表現量之影響 - 85 -
Figure 26. Lazertinib對S1和S1-MI-80蛋白質ABCG2表現量之影響 - 86 -
Figure 27. Lazertinib對ABCB1功能性之影響 - 88 -
Figure 28. Lazertinib對ABCG2功能性之影響 - 90 -

[1] J.P. Jourdan, R. Bureau, C. Rochais, P. Dallemagne, Drug repositioning: a brief overview, J Pharm Pharmacol, 72 (2020) 1145-1151.
[2] J. Langedijk, A.K. Mantel-Teeuwisse, D.S. Slijkerman, M.H. Schutjens, Drug repositioning and repurposing: terminology and definitions in literature, Drug Discov Today, 20 (2015) 1027-1034.
[3] K. Bukowski, M. Kciuk, R. Kontek, Mechanisms of Multidrug Resistance in Cancer Chemotherapy, Int J Mol Sci, 21 (2020).
[4] W. Li, H. Zhang, Y.G. Assaraf, K. Zhao, X. Xu, J. Xie, D.H. Yang, Z.S. Chen, Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies, Drug Resist Updat, 27 (2016) 14-29.
[5] H. Amawi, H.M. Sim, A.K. Tiwari, S.V. Ambudkar, S. Shukla, ABC Transporter-Mediated Multidrug-Resistant Cancer, Adv Exp Med Biol, 1141 (2019) 549-580.
[6] D.M. Hausman, What Is Cancer?, Perspect Biol Med, 62 (2019) 778-784.
[7] P. Greenwald, B.K. Dunn, Landmarks in the history of cancer epidemiology, Cancer Res, 69 (2009) 2151-2162.
[8] E.J. Mun, H.M. Babiker, U. Weinberg, E.D. Kirson, D.D. Von Hoff, Tumor-Treating Fields: A Fourth Modality in Cancer Treatment, Clin Cancer Res, 24 (2018) 266-275.
[9] M. Kartal-Yandim, A. Adan-Gokbulut, Y. Baran, Molecular mechanisms of drug resistance and its reversal in cancer, Crit Rev Biotechnol, 36 (2016) 716-726.
[10] G. Szakacs, J.K. Paterson, J.A. Ludwig, C. Booth-Genthe, M.M. Gottesman, Targeting multidrug resistance in cancer, Nat Rev Drug Discov, 5 (2006) 219-234.
[11] F.L. Theodoulou, I.D. Kerr, ABC transporter research: going strong 40 years on, Biochem Soc Trans, 43 (2015) 1033-1040.
[12] K. Beis, Structural basis for the mechanism of ABC transporters, Biochem Soc Trans, 43 (2015) 889-893.
[13] M. Dean, A. Rzhetsky, R. Allikmets, The human ATP-binding cassette (ABC) transporter superfamily, Genome Res, 11 (2001) 1156-1166.
[14] N.A. Colabufo, M. Contino, M. Niso, F. Berardi, M. Leopoldo, R. Perrone, EGFR tyrosine kinase inhibitors and multidrug resistance: perspectives, Front Biosci (Landmark Ed), 16 (2011) 1811-1823.
[15] T. Kobori, S. Harada, K. Nakamoto, S. Tokuyama, Mechanisms of P-glycoprotein alteration during anticancer treatment: role in the pharmacokinetic and pharmacological effects of various substrate drugs, J Pharmacol Sci, 125 (2014) 242-254.
[16] J.H. Lin, M. Yamazaki, Role of P-glycoprotein in pharmacokinetics: clinical implications, Clin Pharmacokinet, 42 (2003) 59-98.
[17] M.M. Gottesman, I. Pastan, Biochemistry of multidrug resistance mediated by the multidrug transporter, Annu Rev Biochem, 62 (1993) 385-427.
[18] F.J. Sharom, ABC multidrug transporters: structure, function and role in chemoresistance, Pharmacogenomics, 9 (2008) 105-127.
[19] A.H. Schinkel, J.W. Jonker, Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview, Adv Drug Deliv Rev, 55 (2003) 3-29.
[20] Q. Mao, BCRP/ABCG2 in the placenta: expression, function and regulation, Pharm Res, 25 (2008) 1244-1255.
[21] P. Krishnamurthy, J.D. Schuetz, Role of ABCG2/BCRP in biology and medicine, Annu Rev Pharmacol Toxicol, 46 (2006) 381-410.
[22] F. Gori, L. Friedman, M.B. Demay, Wdr5, a novel WD repeat protein, regulates osteoblast and chondrocyte differentiation in vivo, J Musculoskelet Neuronal Interact, 5 (2005) 338-339.
[23] A.F. Bryan, J. Wang, G.C. Howard, A.D. Guarnaccia, C.M. Woodley, E.R. Aho, E.J. Rellinger, B.K. Matlock, D.K. Flaherty, S.L. Lorey, D.H. Chung, S.W. Fesik, Q. Liu, A.M. Weissmiller, W.P. Tansey, WDR5 is a conserved regulator of protein synthesis gene expression, Nucleic Acids Res, 48 (2020) 2924-2941.
[24] G. Senisterra, H. Wu, A. Allali-Hassani, G.A. Wasney, D. Barsyte-Lovejoy, L. Dombrovski, A. Dong, K.T. Nguyen, D. Smil, Y. Bolshan, T. Hajian, H. He, A. Seitova, I. Chau, F. Li, G. Poda, J.F. Couture, P.J. Brown, R. Al-Awar, M. Schapira, C.H. Arrowsmith, M. Vedadi, Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5, Biochem J, 449 (2013) 151-159.
[25] I. Uberall, Z. Kolar, R. Trojanec, J. Berkovcova, M. Hajduch, The status and role of ErbB receptors in human cancer, Exp Mol Pathol, 84 (2008) 79-89.
[26] R. Bose, X. Zhang, The ErbB kinase domain: structural perspectives into kinase activation and inhibition, Exp Cell Res, 315 (2009) 649-658.
[27] J. Baselga, Targeting tyrosine kinases in cancer: the second wave, Science, 312 (2006) 1175-1178.
[28] X.Y. Zhang, Y.K. Zhang, Y.J. Wang, P. Gupta, L. Zeng, M. Xu, X.Q. Wang, D.H. Yang, Z.S. Chen, Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells, Molecules, 21 (2016).
[29] S. Dhillon, Lazertinib: First Approval, Drugs, 81 (2021) 1107-1113.
[30] J. Yun, M.H. Hong, S.Y. Kim, C.W. Park, S. Kim, M.R. Yun, H.N. Kang, K.H. Pyo, S.S. Lee, J.S. Koh, H.J. Song, D.K. Kim, Y.S. Lee, S.W. Oh, S. Choi, H.R. Kim, B.C. Cho, YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer, Clin Cancer Res, 25 (2019) 2575-2587.
[31] S. Pushpakom, F. Iorio, P.A. Eyers, K.J. Escott, S. Hopper, A. Wells, A. Doig, T. Guilliams, J. Latimer, C. McNamee, A. Norris, P. Sanseau, D. Cavalla, M. Pirmohamed, Drug repurposing: progress, challenges and recommendations, Nat Rev Drug Discov, 18 (2019) 41-58.
[32] S.H. Hsiao, Y.J. Lu, Y.Q. Li, Y.H. Huang, C.H. Hsieh, C.P. Wu, Osimertinib (AZD9291) Attenuates the Function of Multidrug Resistance-Linked ATP-Binding Cassette Transporter ABCB1 in Vitro, Mol Pharm, 13 (2016) 2117-2125.
[33] Z. Chen, Y. Chen, M. Xu, L. Chen, X. Zhang, K.K. To, H. Zhao, F. Wang, Z. Xia, X. Chen, L. Fu, Osimertinib (AZD9291) Enhanced the Efficacy of Chemotherapeutic Agents in ABCB1- and ABCG2-Overexpressing Cells In Vitro, In Vivo, and Ex Vivo, Mol Cancer Ther, 15 (2016) 1845-1858.
[34] S. Wu, L. Fu, Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells, Mol Cancer, 17 (2018) 25.
[35] H. Akamatsu, Y. Toi, H. Hayashi, D. Fujimoto, M. Tachihara, N. Furuya, S. Otani, J. Shimizu, N. Katakami, K. Azuma, N. Miura, K. Nishino, S. Hara, S. Teraoka, S. Morita, K. Nakagawa, N. Yamamoto, Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial, JAMA Oncol, 7 (2021) 386-394.
[36] K. Yoneda, N. Imanishi, Y. Ichiki, F. Tanaka, Treatment of Non-small Cell Lung Cancer with EGFR-mutations, J UOEH, 41 (2019) 153-163.
[37] L. Roy, J. Guilhot, T. Krahnke, A. Guerci-Bresler, B.J. Druker, R.A. Larson, S. O'Brien, C. So, G. Massimini, F. Guilhot, Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials, Blood, 108 (2006) 1478-1484.
[38] Y. Fan, T. Tao, Z. Guo, K.K. Wah To, D. Chen, S. Wu, C. Yang, J. Li, M. Luo, F. Wang, L. Fu, Lazertinib improves the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 overexpression cancer cells in vitro, in vivo, and ex vivo, Mol Ther Oncolytics, 24 (2022) 636-649.
[39] R.W. Robey, K.M. Pluchino, M.D. Hall, A.T. Fojo, S.E. Bates, M.M. Gottesman, Revisiting the role of ABC transporters in multidrug-resistant cancer, Nat Rev Cancer, 18 (2018) 452-464.
[40] E.C. Aniogo, B. Plackal Adimuriyil George, H. Abrahamse, The role of photodynamic therapy on multidrug resistant breast cancer, Cancer Cell Int, 19 (2019) 91.